AnaptysBio (ANAB) Competitors $24.04 +0.17 (+0.69%) Closing price 07/3/2025 03:45 PM EasternExtended Trading$23.57 -0.47 (-1.97%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. HCM, OGN, AMRX, MIRM, XENE, BHC, IBRX, GMTX, ARWR, and APLSShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include HUTCHMED (HCM), Organon & Co. (OGN), AMNEAL PHARMACEUTICALS (AMRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors HUTCHMED Organon & Co. AMNEAL PHARMACEUTICALS Mirum Pharmaceuticals Xenon Pharmaceuticals Bausch Health Cos ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals AnaptysBio (NASDAQ:ANAB) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk. Which has more risk and volatility, ANAB or HCM? AnaptysBio has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Which has better valuation & earnings, ANAB or HCM? HUTCHMED has higher revenue and earnings than AnaptysBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M7.74-$145.23M-$4.85-4.96HUTCHMED$630.20M4.40$37.73MN/AN/A Does the media refer more to ANAB or HCM? In the previous week, AnaptysBio had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for AnaptysBio and 3 mentions for HUTCHMED. AnaptysBio's average media sentiment score of 1.11 beat HUTCHMED's score of 0.15 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ANAB or HCM? AnaptysBio presently has a consensus target price of $42.38, suggesting a potential upside of 76.23%. HUTCHMED has a consensus target price of $19.00, suggesting a potential upside of 19.54%. Given AnaptysBio's stronger consensus rating and higher probable upside, equities analysts plainly believe AnaptysBio is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ANAB or HCM more profitable? HUTCHMED has a net margin of 0.00% compared to AnaptysBio's net margin of -125.70%. HUTCHMED's return on equity of 0.00% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-125.70% -282.47% -30.79% HUTCHMED N/A N/A N/A Do insiders & institutionals hold more shares of ANAB or HCM? 8.8% of HUTCHMED shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAnaptysBio beats HUTCHMED on 8 of the 15 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$697.79M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-4.9621.5627.4320.23Price / Sales7.74281.76420.98118.64Price / CashN/A42.7336.8958.07Price / Book10.327.518.045.67Net Income-$145.23M-$55.05M$3.18B$249.13M7 Day Performance7.01%4.61%2.88%3.28%1 Month Performance13.74%4.72%3.69%5.56%1 Year Performance-2.85%5.92%36.15%21.12% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.3443 of 5 stars$24.05+0.7%$42.38+76.2%-3.4%$697.79M$91.28M-4.96100News CoveragePositive NewsInsider TradeHCMHUTCHMED1.656 of 5 stars$15.05-0.3%$19.00+26.2%-9.3%$2.63B$630.20M0.001,811OGNOrganon & Co.4.8946 of 5 stars$9.68-1.8%$18.00+86.0%-50.4%$2.56B$6.40B2.724,000Trending NewsAMRXAMNEAL PHARMACEUTICALS3.2095 of 5 stars$8.09-0.5%$11.60+43.4%+26.8%$2.55B$2.79B13.788,100High Trading VolumeMIRMMirum Pharmaceuticals3.7416 of 5 stars$50.89-0.4%$65.50+28.7%+47.4%$2.53B$336.89M0.00140News CoverageXENEXenon Pharmaceuticals2.9954 of 5 stars$31.30-3.4%$54.82+75.1%-3.9%$2.49B$9.43M-9.69210BHCBausch Health Cos3.1366 of 5 stars$6.68+3.4%$7.42+11.0%-2.8%$2.39B$9.63B1.7220,700IBRXImmunityBio1.874 of 5 stars$2.64-2.2%$12.25+364.0%-57.0%$2.38B$14.74M0.00590Negative NewsGap UpGMTXGemini TherapeuticsN/A$54.50+0.7%N/A+23.2%$2.36BN/A-54.5030High Trading VolumeARWRArrowhead Pharmaceuticals3.9959 of 5 stars$15.80-1.7%$43.71+176.7%-33.1%$2.22B$3.55M-11.29400APLSApellis Pharmaceuticals4.4456 of 5 stars$17.31-0.7%$40.05+131.4%-49.2%$2.19B$781.37M0.00770Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies HUTCHMED Competitors Organon & Co. Competitors AMNEAL PHARMACEUTICALS Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Bausch Health Cos Competitors ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts